Lidocaine Aguettant (Lidocaine Hydrochloride)

Lidocaine acts as a local anesthetic and antiarrhythmic agent, providing reversible nerve block and cardiac membrane stabilization.

• Minor surgical procedures: enables pain‑free operation of superficial tissues.
• Infiltration anesthesia: numbs targeted tissue for diagnostic or therapeutic injections.
• Intradermal anesthesia: used for skin testing and minor dermatologic procedures.
• Intravenous antiarrhythmic therapy: stabilizes cardiac rhythm in selected arrhythmias.

• Lidocaine exerts its effect by reversibly binding to the intracellular portion of voltage‑gated sodium channels in neuronal and cardiac membranes. This blockade prevents the rapid influx of sodium ions during depolarization, thereby inhibiting the generation and propagation of nerve impulses and reducing abnormal cardiac excitability.

Lidocaine may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Transient burning or tingling at the injection site.
• Mild dizziness or light‑headedness.
• Nausea or mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Systemic toxicity presenting as central nervous system depression, seizures, or coma.
• Cardiac arrhythmias, including bradycardia or ventricular tachycardia.
• Allergic reactions ranging from urticaria to anaphylaxis.

When using Lidocaine, consider the following safety measures.

• Allergy assessment: confirm no known hypersensitivity to amide‑type local anesthetics.
• Cardiovascular status: avoid in patients with severe heart block or conduction disorders.
• Dosage limits: adhere to recommended maximum doses to prevent systemic toxicity.
• Concurrent CNS depressants: monitor for additive sedative effects.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Lidocaine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase lidocaine plasma levels.
• CYP3A4 inhibitors (e.g., ketoconazole): can raise systemic exposure.
• Beta‑blockers (e.g., propranolol): may enhance cardiac effects.

Moderate Interactions (Monitor Closely)

• Class III antiarrhythmics (e.g., amiodarone): may affect lidocaine metabolism.
• Other local anesthetics: cumulative toxicity risk.
• Diuretics (e.g., furosemide): may alter plasma protein binding.